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Purpose: The role of Chlamydia trachomatis  (CT) infection in chronic bacterial prostatitis (CBP) is well known. What is unclear is 
whether there are any differences in the course or clinical outcome of the disease when the cause is CT or other uropathogens.
Materials and Methods: A series of 311 patients affected by CBP due to CT (cohort A) was compared with a group of 524 patients 
affected by CBP caused by common uropathogen bacteria (cohort B). All participants completed the following questionnaires: Na-
tional Institutes of Health Chronic Prostatitis Symptom Index, International Prostate Symptom Score, International Index of Erectile 
Function-15 erectile function domain (IIEF-15-EFD), Premature Ejaculation Diagnostic Tool (PEDT), and the Short Form 36 (SF-36) 
Health Survey. All patients were followed with clinical and microbiological evaluations.
Results: After a mean follow-up time of 42.3 months, the number of symptomatic episodes was significantly higher in patients in 
cohort A than in cohort B (4.1±1.1 vs. 2.8±0.8, p<0.001), and the mean time to first symptomatic recurrence was shorter in cohort 
A than in cohort B (3.3±2.3 months vs. 5.7±1.9 months, p<0.001). Moreover, scores on the SF-36 tool were significantly lower in 
cohort A (96.5±1.0 vs. 99.7±1.9, p<0.001) at the first symptomatic recurrence. Cohort A also showed significantly lower scores on 
the IIEF-15-EFD and PEDT questionnaires at the end of the follow-up period (26.8±2.9 vs. 27.3±3.3, p=0.02 and 11.5±2.3 vs. 4.5±2.8, 
p<0.001, respectively).
Conclusions: Patients affected by CBP due to CT infection have a higher number of symptomatic recurrences with a more severe 
impact on quality of life.
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INTRODUCTION
Chlamydia trachomatis (CT) is the most common cause 
of sexually transmitted infections (STIs) worldwide [1]. It is 
well established that in male patients CT can be one of the 
causes of lower urinary and male genital tract infections, 
with prostatitis-like symptoms and decreased fertility 
impairing male health [2,3]. CT has been accepted as a 
causative agent of chronic bacterial prostatitis (CBP), and for 
this reason testing for this pathogen is highly recommended 
[4]. Even if  more than 50% of  men with CT infections 
are asymptomatic, acute manifestation of the infection is 
responsible for a number of symptoms, infertility, and long-
term reduced quality of life [5,6]. In addition, it has been 
demonstrated that CBP due to CT is an important organic 
cause of  premature ejaculation, affecting the prostate 
ejaculation process [7]. Moreover, the treatment of prostate 
CT infection can be a real challenge for urologists, with 
the result being multiple recurrences and persistency 
of  infection. The National Institutes of  Health (NIH) 
classification of prostatitis includes all CBP, regardless of 
the causative agent, in class II [8]. Therefore, CBP due to CT 
is in the same category as that caused by common bacteria. 
It is unclear, however, whether there are any differences in 
the course or clinical outcome of the disease when the cause 
is CT or other uropathogens. In the present study, we aimed 
to evaluate the natural history, clinical characteristics, and 
outcome of CT infection compared with infection due to 
common uropathogens.
MATERIALS AND METHODS
1. Study design
All patients with clinical, microbiological, or inst-
rumental diagnosis of  CBP and attending the same STI 
clinic from January 2008 to December 2010 for prostatitis 
treatment and management were consecutively enrolled in 
this prospective parallel-cohort study. We chose this kind 
of study because in a prospective parallel-cohort study the 
groups of individuals (cohorts) are selected on the basis of 
certain factors and followed for a period of time to discover 
a possible relationship on defined outcomes [9].
2. Population
All enrolled patients were divided into 2 groups 
according to the microbiological findings: cohort A included 
patients with CBP resulting from CT infection, and 
cohort B included patients with CBP caused by common 
uropathogenic bacteria.
Assignment to each cohort was determined by molecular, 
immunologic, and culture results as follows. Cohort A includ-
ed patients with positive results for CT DNA amplification 
in expressed prostatic secretions (EPS) and/or postprostatic 
massage urine (VB3) samples obtained from the Meares and 
Stamey test and negative results for common uropathogens. 
Cohort B included patients with negative results for CT 
DNA amplification and positive results for the following 
bacteria, considered as uropathogens: enteric gram-negative 
rods, enterococci, Staphylococcus saprophyticus, and group B 
streptococci [10].
3. Inclusion and exclusion criteria
Inclusion criteria for this study were a clinical and 
microbiological diagnosis of  CBP (category II, NIH cla-
ssification) and symptoms lasting more than 6 mon ths. 
Diagnostic procedures for CBP were carried out in accor-
dance with European Association of Urology guide lines [11]. 
Patients <18 and >45 years of age, with major concomitant 
diseases or anatomic abnormalities of  the genital and 
urinary tracts were excluded. Moreover, patients with 
positive findings for CT infection in the first-voided urine 
specimen (VB1) or the midstream urine sample (VB2) 
of  the Meares and Stamey test were excluded as well. 
Isolated positivity to serum anti-CT IgA and/or IgG was not 
considered a sufficient diagnostic criterion for CT infection, 
and therefore such patients were also excluded.
4. Microbiological considerations
All patients underwent a full microbiological diagnostic 
workup including cultures in order to detect common 
uropathogenic bacteria and yeasts, DNA extraction, and 
mucosal IgA evaluation for CT diagnosis and a Meares-
Stamey four-glass test, performed according to the European 
Association of  Urology guidelines [11]. Semen samples 
for culture were also collected and analyzed [11]. Genital 
samples were collected from each patient in accordance with 
indications described in a previous report: early-morning 
VB1, VB2, EPS, VB3, and seminal sample were sampled in 
sequence [12]. A culture of a urethral swab on each patient 
was performed to rule out urethritis as a result of  CT 
infection [5,12]. The Meares-Stamey 4-glass test indicates the 
presence of bacterial prostatitis only if the bacterial load in 
the EPS or VB3 is at least 1,000 colony-forming units/mL 
and at least 10 times higher than in VB1 or VB2. Moreover, 
we considered a positive Meares-Stamey test result for every 
patient found with a significant number of bacteria in EPS 
and/or VB3. All samples were collected and immediately 
transferred to the laboratory, under refrigerated conditions, 
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to be analyzed for cultures, DNA extraction, and polymerase 
chain reaction as described previously [5,12]. In accordance 
with Nickel et al. [13], the white blood cell count in all 
biological samples was obtained but not considered in this 
study. Each patient also underwent serum IgA and IgG 
anti-CT analysis. Blood sample collection was performed 
on arrival at the STI Centre [5]. Mucosal IgA was detected 
by a modified version of the IPAzyme Chlamydia IgG/IgA 
immunoperoxidase test (Savyon Diagnostics, Ashdod, Israel) 
[5]. We assigned a predefined score (i.e., from 1+ to 20+ points) 
in an attempt to quantitatively define the levels of mucosal 
IgA present in all samples, according to Mazzoli et al. [5]. 
The “plus” value of each score was dependent on the color 
intensity of intracellular inclusions caused by CT in infected 
fibroblasts, which was utilized as antigen in the analytical 
procedure and evaluated by microscopic reading (400 
magnifications) [5]. Analysis of IgA in mucosal secretions 
analysis was performed by CT IgG + IgA Western blot 
(AID Autoimmun Diagnostika GmbH, Straberg, Germany). 
Blotted CT proteins were lipopolysaccharide (2 fractions), 
major outer membrane protein 1 (MOMP; 2 fractions), 
MOMP 2 (29, 45, 80 kD), HSP 60, and HSP 70.
5. Questionnaires and clinical examinations
The Italian versions of the following validated question-
naires were administered to each patient at the first visit 
and at each follow-up visit, as is routine practice in our 
center:
•	NIH	Chronic	Prostatitis	Symptom	Index	(NIH-CPSI)	[14],
•	International	Prostate	Symptom	Score	(IPSS)	[15],
•	International	Index	of 	Erectile	Function-15	erectile	
function	domain	(IIEF-15-EFD)	[16],
•	SF-36	Health	Survey	[17],	
•	Premature	Ejaculation	Diagnostic	Tool	(PEDT)	[18].
In accordance with Nickel et al. [19], prostatitis-like 
symptoms were considered significant at an NIH-CPSI pain 
score equal to or higher than 4.
6. Study schedule
Once enrolled, all patients were scheduled for annual 
follow-up visits at the end of  the therapy, and in the 
presence of symptoms, until the end of the follow-up period. 
At each follow-up visit they were asked to complete the 
questionnaires and underwent clinical and microbiological 
examinations. All symptomatic recurrences were recorded 
and treated with antibiotics, depending on the organism, 
according to susceptibility testing, in line with the 
European Association of Urology guidelines [11]. In cohort 
B, all patients were treated in line with the antibiogram 
findings, whereas in cohort A, the treatment was performed 
according to the European Association of Urology guidelines: 
tetracyclines (doxycycline) or levofloxacin [11]. Partners were 
treated as well, and the use of condoms was advised to all 
patients in cohort B during the antibiotic therapy, as is 
common practice in our center. All patients with persistent 
infection by the same pathogen at the posttreatment 
microbiological evaluation were excluded. On the other hand, 
not all patients with recurrent infection were excluded. 
We compared the two cohorts of patients considering the 
following parameters:
•	Number	of	symptomatic	episodes	per	patient	counted	
at the end of the follow-up period.
•	Time	at	first	recurrence.
•	Mean	score	on	the	NIH-CPSI,	IPSS,	IIEF-15-EFD,	SF-
36, and PEDT questionnaire administered at the end of 
the follow-up period.
7. Statistical and ethical considerations
As a null hypothesis, we assumed that there was no 
significant difference between cohorts A and B in terms of 
number of symptomatic recurrences per patient and mean 
score	on	all	the	questionnaires.	For	sample	characterization	
and assessment of  the distribution of  scores, descriptive 
statistics were used, including measures of central tendency 
(mean) and dispersion (standard deviation) for quantitative 
variables and frequency for categorical variables. All 
variables were subsequently coded for analysis as continuous 
or categorical in accordance with their characteristics. 
Data were presented as the mean±standard deviation. We 
compared the 2 cohorts at enrollment by using a 2-tailed 
Student t-test for paired/unpaired data and a chi-square 
analysis for the comparison of proportions. All variables of 
interest were collected during urological examinations and 
recorded in a dedicated database (Advanced PROSTATitis 
DataBase, Microsoft Access format). Statistical significance 
was achieved in the presence of an alpha-error inferior to 0.05. 
All reported p-values were 2-sided. All data were recorded, 
collected, and analyzed by using IBM SPSS 20.0 for Apple-
Macintosh (IBM Co., Armonk, NY, USA). The local research 
ethics committee approved the present study (Department 
of	Urology;	University	of	Florence;	URO_Data_3_2007),	and	
written informed consent was obtained from all patients 
before their enrollment. The study was conducted in line 
with Good Clinical Practice guidelines and in line with the 
STROBE (Strengthening the Reporting of  Observational 
Studies in Epidemiology) statement (http://www.strobe-
statement.org).
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RESULTS
From	a	total	population	of 	3,127	consecutive	patients	
attending our STI centre with a confirmed diagnosis of CBP 
(category II, NIH classification) with symptoms lasting >6 
months, 978 patients were considered eligible for the study. 
One hundred three patients were excluded for lack of data 
collection and 40 were lost to follow-up. In the end, 835 
Caucasian patients (mean age, 33.6±7.1 years) were enrolled: 
311 in cohort A and 524 in cohort B (Fig.	1). Anamnestic 
and clinical data at enrollment are shown in Table 1. The 
2 cohorts of patients were comparable in terms of age and 
clinical characteristics. At the time of  enrollment, the 2 
cohorts had comparable distributions of NIH-CPSI (p=0.70), 
IPSS	(p=0.15),	and	IIEF-15-EFD	(p=0.19)	scores.	Compared	to	
cohort B, cohort A had significantly worse scores on the 
PEDT test (11.4±2.7 vs. 4.8±2.7, p<0.001) and lower scores on 
the	SF-36	tool	(96.1±1.3	vs.	99.7±1.8,	p<0.001).
1. Microbiological results at the time of enrollment
From	the	835	studied	cases,	2,765	genitourinary	samples	
were collected and analyzed. Three hundred eleven patients 
(37.3%) had positive results for mucosal anti-CT IgA in 
urogenital samples and/or CT-DNA but had negative results 
for cultures for other bacteria or yeasts. These patients were 
allocated	to	Cohort	A.	Five	hundred	twenty-four	patients	
(62.7%) had positive results for common uropathogens but 
not for CT and were allocated to Cohort B. Table 2 lists the 
microbiological findings in both groups.
2. Treatment at the first evaluation and at the end 
of the study period
At the first evaluation, all patients in cohort B had been 
treated in line with the microbiological results. The most 
commonly used antibiotics were levofloxacin (378 of 524, 
72.1%), ciprofloxacin (102 of 524, 19.5%) and cotrimoxazole (25 
of 524, 4.7%). In cohort A the most commonly used antibiotic 
was doxycycline (289 of 311, 92.9%). The median treatment 
time was 4 weeks in cohort A and 2 weeks in cohort B.
At the end of the study period, the most commonly used 
antibiotics in cohorts A and B were the same as shown in 
the first evaluation.
3. Clinical evaluation, questionnaire, and micro-
biological results at the end of the study period
After a mean follow-up of 42.3 months, cohort A showed 
a significantly higher number of  symptomatic episodes 
than did cohort B (4.1±1.1 vs. 2.8±0.8, p<0.001) and a shorter 
mean time to first symptomatic recurrence (3.3±2.3 months 
vs. 5.7±1.9 months, p<0.001). Fig.	2 shows the Kaplan-Meier 
curves of the risk of recurrence in the 2 cohorts. Compared 
to cohort B, cohort A showed significantly worse scores on 
the	SF-36	tool	(96.5±1.0	vs.	99.7±1.9,	p<0.001),	IIEF-15-EFD	
(26.8±2.9 vs. 27.3±3.3, p=0.02), and PEDT questionnaire (11.5±2.3 
vs. 4.5±2.8, p<0.001) at the end of the follow-up period. No 
significant differences in terms of urinary symptoms were 
reported on the IPSS (8.7±1.5 vs. 8.9±1.9, p=0.10) or NIH-CPSI 
(19.9±7.1 vs. 19.8±8.3, p=0.85). Table 3 shows all clinical and 
microbiological results at the end of the follow-up period.
Assessed for eligibility (n=978)
Prospective data
collection
(Jan 2008-Dec 2010)
Analysis
(mean follow-up: 42.3 months)
Analysed (n=311)
Excluded from analysis (n=15)
Lost during the follow-up
Cohort A: CT infection
Analysed (n=524)
Excluded from analysis (n=25)
Lost during the follow-up
Cohort B: Uropathogen infection
Allocated to Cohort A (n=361)
Patients with CP due to CT infection
Allocated to Cohort B (n=617)
Patients with CP due to uropathogens
Excluded for data lacking (n=35)
Lost during the follow-up
Excluded for data lacking (n=68)
Lost during the follow-up
Fig. 1. The study flow chart in line with 
the STROBE (Strengthening the Report-
ing of Observational Studies in Epidemi-
ology) statement (http://www.strobe-
statement.org). Cohort A, patients with 
chronic bacterial prostatitis resulting 
from Chlamydia trachomatis infection; 
Cohort B, patients with chronic bacterial 
prostatitis due to common uropatho-
gens; CP, chronic prostatitis; CT, Chla-
mydia trachomatis .
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DISCUSSION
In the present study we focused our attention on the 
natural history of CBP due to CT infection, hypothesizing 
that the clinical characteristics of patients affected by CBP 
due to CT infection would differ from those of patients with 
CBP due to common uropathogens. We hereby demonstrated 
that patients with CBP due to CT infection reported a 
higher number of symptomatic episodes with a shorter mean 
time to first symptomatic recurrence. Moreover, patients 
affected	by	CT	infection	reported	lower	scores	on	the	SF-
36,	IIEF-15-EFD,	and	PEDT	questionnaires,	demonstrating	a	
higher impact on the patient’s quality of life.
The impact of bacterial strains on the clinical outcome 
of patients has not been analyzed in depth. Several authors 
have demonstrated the role of CT as a causative pathogen, 
but to date no study has been performed to demonstrate the 
role of bacterial type in the natural history of the disease. On 
the one hand, Park et al. [20] demonstrated that the presence 
of CT infection is associated with a higher pain score and 
can worsen quality of life in patients with chronic prostatitis 
or chronic pelvic pain syndrome (CP/CPPS). On the other 
Table 1. Sociodemographic, anamnestic, and clinical characteristics of the patients at the time of enrolment
Variable Cohort A (n=311) Cohort B (n=524) p-value
Age (y) 33.3±5.2 33.8 ±5.4 0.43
Educational qualification 0.51
   Primary school 1 (0.3) 2 (0.4)
   High school 179 (57.5) 314 (59.9)
   University 131 (42.2) 208 (39.7)
Smoking 1.0
   Yes 121 (38.9) 203 (38.7)
   No 190 (61.1) 321 (61.3)
Body mass index (kg/m2) 28.6±2.3 28.9±2.7 0.10
Comorbidities 1.0
   Hypertension or cardiovascular diseases 2 (0.6) 3 (0.5)
   Diabetes mellitus 1 (0.3) 2 (0.4)
   No 308 (99.1) 519 (99.1)
Circumcised 0.83
   Yes 9 (2.9) 17 (3.2)
   No 302 (97.1) 507 (96.8)
Sexually active (past month) 308 (99.0) 519 (99.1) 1.0
Sexual behavior 0.60
   1 partner 248 (79.7) 409 (78.1)
   >1 partner 63 (20.3) 115 (21.9)
Contraceptive use 0.75
   Condom 214 (68.8) 366 (69.8)
   Coitus interruptus 97 (31.2) 158 (30.2)
Start of CP history (y) 2.5±1.7 2.7±1.5 0.07
Clinical presentation 0.72
   Urinary symptoms 108 (34.7) 183 (34.9)
   Pain 51 (16.3) 78 (14.9)
   Pain + urinary symptoms 152 (49.0) 263 (50.2)
NIH-CPSI (0–43) 19.5±7.2 19.7±7.6 0.70
IPSS (0–35) 8.8±1.9 9.0±2.0 0.15
IIEF-15-EFD (0–30) 26.7±3.1 27.0±3.3 0.19
SF-36 (0–100) 96.1±1.3 99.7±1.8 <0.001
PEDT (0–20) 11.4±2.7 4.8±2.7 <0.001
Values are presented as mean±standard deviation or number (%). The table shows all anamnestic and clinical data at the time of enrolment. 
Cohort A, patients with chronic bacterial prostatitis resulting from Chlamydia trachomatis infection; Cohort B, patients with chronic bacterial 
prostatitis due to common uropathogens; CP, chronic prostatitis; NIH-CPSI, NIH Chronic Prostatitis Symptom Index; IPSS, International Prostate 
Symptom Score; IIEF-15-EFD, International Index of Erectile Function-15 erectile function domain; SF-36, Short Form 36 Health Survey; PEDT, Pre-
mature Ejaculation Diagnostic Tool.
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hand, Cai et al. [7] demonstrated that patients affected by 
CBP due to CT infection reported a higher prevalence of 
premature ejaculation and a lower sexual quality of life. In 
this sense, the presence of CT infection should be considered 
as a risk factor for a worsened general and sexual quality 
of life. Mazzoli et al. [5], in addition, highlighted the fact 
that the level of mucosal anti-CT antibodies (mucosal IgA) is 
correlated with interleukin (IL)-8 levels and symptom scores 
in patients with CP/CPPS. Moreover, patients with higher 
levels of IL-8 and higher positivity for mucosal IgA reported 
the worst symptoms [5]. Koroku et al. [21] also demonstrated 
that the presence of CT infections is related to a higher 
rate of white blood cells in EPS in CP/CPPS patients. In our 
population, we found that patients with CBP due to common 
uropathogens showed a lower number of  symptomatic 
episodes in the whole study period than did patients with 
CBP due to CT (2.8 vs. 4.1). The natural history of CBP due 
to common uropathogens is quite similar to that shown by 
Nickel et al. [22] in a 1-year follow-up study. Nickel et al. [22] 
demonstrated that 63% of patients experienced persistent 
symptoms and reported at least one symptomatic episode in 
12 months. The same results were also reported by Turner et 
al. [23]. The symptomatic recurrences observed in the cohort 
of patients affected by CT infection are probably due to the 
fact that the microbiological eradication and the clinical 
cure are not optimal; Skerk et al. [24] reported an eradication 
rate of about 80% of all patients treated with azithromycin.
There were several important strengths to our study. 
The first was the prospective nature of the study design 
and the large patient population. The fact that all patients 
were evaluated in a single center is another strength; as 
a result, the patient selection and evaluation criteria were 
the same, as were the microbiological evaluation and follow-
up visits. CT is a rare and nontraditional pathogen in CBP. 
In this study we performed an accurate microbiological 
assessment by using urethral swabs to exclude all patients 
with urethritis. Moreover, the long-term follow-up period 
was another point that gave strength to the study. It is 
well known that sexual function and other prostatitis-like 
symptoms can be related to age, smoking, or other clinical 
characteristics. Our cohorts of patients were homogeneous 
in terms of  sociodemographic, anamnestic, and clinical 
characteristics. In this sense, the differences between the 
two groups in terms of sexual function were fully correlated 
to CT infection. 
On the other hand, a few limitations should be taken 
into	account.	First,	our	study	population	was	composed	of	
patients referred by second- or third-level specialized centers. 
Table 2. Microbiological findings at the time of enrollment
Variable Cohort A (n=311) Cohort B (n=524)
Chlamydia trachomatis  plasmid DNA positive 311 (100) -
Chlamydia trachomatis  secretory IgA positive 103 (33.1)
Chlamydia trachomatis  serum IgA positive 124 (39.8) -
Chlamydia trachomatis  serum IgG positive 130 (41.8) -
Both Chlamydia trachomatis serum IgA and IgG positive 57 (18.4) -
Uropathogen strains
   Enterococcus species - 253 (48.3)
   Escherichia coli - 214 (40.7)
   Klebsiella species - 22 (4.3)
   Serratia species - 19 (3.7)
   Staphylococcus saprophyticus - 16 (3.0)
Values are presented as number (%).
Cohort A, patients with chronic bacterial prostatitis resulting from Chlamydia trachomatis infection; Cohort B, patients with chronic bacterial 
prostatitis due to common uropathogens.
Fig. 2. Kaplan-Meier curves of the risk of recurrence in the 2 cohorts. 
Cohort A, patients with chronic bacterial prostatitis resulting from 
Chlamydia trachomatis infection; Cohort B, patients with chronic 
bacterial prostatitis due to common uropathogens. Long-rank test: 
p<0.001.
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It is also true that we analyzed a large cohort of patients 
and this might reflect various clinical scenarios found 
in a more general patient population. We highlight that 
assigning	sexual	function	status	solely	on	the	basis	of	IIEF	
and PEDT questionnaires could be considered a limitation 
of this study. Some authors have argued that the specificity 
of  questionnaires is relatively low as a reliable tool in 
diagnosing male sexual dysfunction [25].
This study highlights 2 key aspects to consider in 
everyday clinical practice: the presence of  CT infection 
in patients with CBP should be considered as a marker 
associated with a worse clinical outcome. Chlamydia 
infection is a common STI. Patients with this strain 
are	questioned	about	a	 low	 IIEF-15-EDF	score	and	a	
high PEDT score. Therefore, diagnostic tests for CT are 
highly recommended for patients with prostatitis-like 
symptoms. The treatment, even when carried out in line 
with the European Association of  Urology guidelines or 
international recommendations, cannot prevent the risk 
of  new recurrences. It is likely that antibiotic therapy 
cannot fully eradicate the infection, especially when faced 
with an intracellular pathogen located in prostate tissue. 
For	this	reason,	greater	attention	should	be	given	to	those	
patients with a known history of CT infection because they 
carry a greater risk of early recurrence, even if the results 
of  microbiological analysis after the first treatment are 
negative. 
CONCLUSIONS
In conclusion, patients affected by chronic prostatitis due 
to CT have a higher number of symptomatic recurrences 
that more severely impair general and sexual quality of 
life compared with patients affected by chronic prostatitis 
caused by traditional uropathogenic bacteria. Additional 
prospective studies are needed to clarify the role of 
inflammation and infection of the prostate gland due to CT 
and other pathogens.
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Table 3. Clinical and microbiological findings at the end of the follow-up period
Variable Cohort A (n=311) Cohort B (n=524) p-value
Patients with at least one symptomatic recurrence 89/311 (28.6) 65/524 (12.4) <0.001
Symptomatic recurrence 4.1±1.1 2.8±0.8 <0.001
Mean time at first symptomatic recurrence (mo) 3.3±2.3 5.7±1.9 <0.001
Questionnaire mean scores
   NIH-CPSI (0–43) 19.9±7.1 19.8±8.3 0.85
   IPSS (0–35) 8.7±1.5 8.9±1.9 0.10
   IIEF-15-EFD (0–30) 26.8±2.9 27.3±3.3 0.02
   SF-36 (0–100) 96.5±1.0 99.7±1.9 <0.001
   PEDT (0–20) 11.5±2.3 4.5±2.8 <0.001
Microbiological findings
Uropathogen strains
   Enterococcus species - 31 (47.7)
   Escherichia coli - 23 (35.4)
   Klebsiella species - 7 (10.8)
   Serratia species - 4 (6.1)
Chlamydia trachomatis plasmid DNA positive 89 (100) -
Chlamydia trachomatis secretory IgA positive 33 (37.1) -
Values are presented as number (%) or mean±standard deviation. 
Cohort A, patients with chronic bacterial prostatitis resulting from Chlamydia trachomatis infection; Cohort B, patients with chronic bacterial 
prostatitis due to common uropathogens; NIH-CPSI, NIH Chronic Prostatitis Symptom Index; IPSS, International Prostate Symptom Score; IIEF-15-
EFD, International Index of Erectile Function-15 erectile function domain; SF-36, Short Form 36 Health Survey; PEDT, Premature Ejaculation Diag-
nostic Tool.
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